Observational studyNeurology2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
Observational study in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Trial
- Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.Journal of neurology · 2025Review
- Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammation.Journal of translational medicine · 2025Article
- Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.Royal Society open science · 2025Review
- Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.Neurology · 2023Article
- Recurrent disability progression endpoints in multiple sclerosis clinical trials.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.International journal of environmental research and public health · 2022Article
- How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?Journal of central nervous system disease · 2022Article
- Human umbilical cord mesenchymal stem cell-derived extracellular vesicles attenuate experimental autoimmune encephalomyelitis via regulating pro and anti-inflammatory cytokines.Scientific reports · 2021Article
- Determinants of disability development in patients with multiple sclerosis.Arquivos de neuro-psiquiatria · 2021Article
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.Neurology · 2021Article
- Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.Multiple sclerosis international · 2020Article
- Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.Neurology and therapy · 2019Article
- Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.JAMA neurology · 2019Article
- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.JAMA neurology · 2018Observational
- Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.International journal of molecular sciences · 2018Review
- Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.Nature reviews. Neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS).
methodsUsing MSBase, an international cohort study, we previously validated a highly accurate definition of SPMS. Here, we identified patients in MSBase who were either untreated or treated with a disease-modifying drug when meeting this definition. Propensity score matching was used to select subpopulations with comparable baseline characteristics. Disability outcomes were compared in paired, pairwise-censored analyses adjusted for treatment persistence, visit density, and relapse rates.
resultsOf the 2,381 included patients, 1,378 patients were matchable (treated n = 689, untreated n = 689). Median pairwise-censored follow-up was 2.1 years (quartiles 1.2-3.8 years). No difference in the risk of 6-month sustained disability progression was observed between the groups (hazard ratio [HR] 0.9, 95% confidence interval [CI] 0.7-1.1,
conclusionsOur pooled analysis of the currently available disease-modifying agents used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.